370 related articles for article (PubMed ID: 33612190)
21. The influence of familial networks and stigma on prison-based medication initiation for individuals with opioid use disorder: Clinicians' perceptions.
Rockett ML; Knudsen HK; Oser CB
J Subst Use Addict Treat; 2024 Jul; 162():209353. PubMed ID: 38521351
[TBL] [Abstract][Full Text] [Related]
22. Medication for Opioid Use Disorder During Pregnancy - Maternal and Infant Network to Understand Outcomes Associated with Use of Medication for Opioid Use Disorder During Pregnancy (MAT-LINK), 2014-2021.
Miele K; Kim SY; Jones R; Rembert JH; Wachman EM; Shrestha H; Henninger ML; Kimes TM; Schneider PD; Sivaloganathan V; Sward KA; Deshmukh VG; Sanjuan PM; Maxwell JR; Seligman NS; Caveglia S; Louis JM; Wright T; Bennett CC; Green C; George N; Gosdin L; Tran EL; Meaney-Delman D; Gilboa SM
MMWR Surveill Summ; 2023 May; 72(3):1-14. PubMed ID: 37130060
[TBL] [Abstract][Full Text] [Related]
23. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids.
Winhusen T; Wilder C; Lyons MS; Theobald J; Kropp F; Lewis D
Drug Alcohol Depend; 2020 Nov; 216():108265. PubMed ID: 32919098
[TBL] [Abstract][Full Text] [Related]
25. The Lived Experience of Medication for Opioid Use Disorder: Qualitative Metasynthesis.
Techau A; Gamm E; Roberts M; Garcia L
J Addict Nurs; 2023 Jul-Sep 01; 34(3):E119-E134. PubMed ID: 37669351
[TBL] [Abstract][Full Text] [Related]
26. Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.
Treitler P; Enich M; Bowden C; Mahone A; Lloyd J; Crystal S
J Subst Use Addict Treat; 2024 Jan; 156():209212. PubMed ID: 37935350
[TBL] [Abstract][Full Text] [Related]
27. The development of a recovery coaching training curriculum to facilitate linkage to and increase retention on medications for opioid use disorder.
Moffitt T; Fallin-Bennett A; Fanucchi L; Walsh SL; Cook C; Oller D; Ross A; Gallivan M; Lauckner J; Byard J; Wheeler-Crum P; Lofwall MR
Front Public Health; 2024; 12():1334850. PubMed ID: 38425462
[TBL] [Abstract][Full Text] [Related]
28. Whose opinion matters about medications for opioid use disorder? A cross-sectional survey of social norms among court staff.
Andraka-Christou B; Atkins DN
Subst Abus; 2021; 42(4):735-750. PubMed ID: 33284059
[No Abstract] [Full Text] [Related]
29. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.
Andraka-Christou B; Clark MH; Atkins DN; Del Pozo B
Subst Abus; 2022; 43(1):425-432. PubMed ID: 34236297
[No Abstract] [Full Text] [Related]
30. Influences on advance practice nursing education to prescribe medications for opioid use disorder.
Phoenix BJ; Tierney M; Chapman SA; Spetz J
Nurs Outlook; 2023; 71(3):101963. PubMed ID: 37003088
[TBL] [Abstract][Full Text] [Related]
31. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
Booty MD; Harp K; Batty E; Knudsen HK; Staton M; Oser CB
J Subst Use Addict Treat; 2023 Jun; 149():209051. PubMed ID: 37084815
[TBL] [Abstract][Full Text] [Related]
32. Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States.
Paschen-Wolff MM; Velasquez R; Aydinoglo N; Campbell ANC
J Subst Abuse Treat; 2022 Sep; 140():108828. PubMed ID: 35749919
[TBL] [Abstract][Full Text] [Related]
33. Mobile treatment for opioid use disorder: Implementation of community-based, same-day medication access interventions.
Chatterjee A; Baker T; Rudorf M; Walt G; Stotz C; Martin A; Kinnard EN; McAlearney AS; Bosak J; Medley B; Pinkhover A; Taylor JL; Samet JH; Lunze K
J Subst Use Addict Treat; 2024 Apr; 159():209272. PubMed ID: 38128649
[TBL] [Abstract][Full Text] [Related]
34. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Brezel ER; Powell T; Fox AD
Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
[TBL] [Abstract][Full Text] [Related]
35. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
36. Using machine learning to study the effect of medication adherence in Opioid Use Disorder.
Warren D; Marashi A; Siddiqui A; Eijaz AA; Pradhan P; Lim D; Call G; Dras M
PLoS One; 2022; 17(12):e0278988. PubMed ID: 36520864
[TBL] [Abstract][Full Text] [Related]
37. "I think we're getting better but we're still not there": Provider-based stigma and perceived barriers to care for people who use opioids (PWUO).
McLean K; Murphy J; Kruis N
J Subst Use Addict Treat; 2024 Apr; 159():209270. PubMed ID: 38103831
[TBL] [Abstract][Full Text] [Related]
38. Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population.
Cole ES; Drake C; DiDomenico E; Sharbaugh M; Kim JY; Nagy D; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kmiec J; Kelley D; Donohue JM
Drug Alcohol Depend; 2021 Apr; 221():108633. PubMed ID: 33631544
[TBL] [Abstract][Full Text] [Related]
39. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
[TBL] [Abstract][Full Text] [Related]
40. Drug court utilization of medications for opioid use disorder in high opioid mortality communities.
Marlowe DB; Theiss DS; Ostlie EM; Carnevale J
J Subst Abuse Treat; 2022 Oct; 141():108850. PubMed ID: 35931014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
